ANDOVER, Massachusetts, Feb. 23, 2016 /PRNewswire/ -- TransMedics, Inc., the global leader in portable ex-vivo warm perfusion of donor organs for transplantation, announces the world's first human liver transplantation using the OCS™ Liver technology and the initiation of the OCS™ Liver PROTECT Pivotal Trial.
The transplant procedure was performed by Dr. James F. Markmann, Chief of Transplant Surgery at Massachusetts General Hospital. Dr. Markmann is a principal investigator and Chairman of the Steering Committee for the PROTECT Trial. "It is our hope that the ability to preserve a liver in the manner offered by the OCS technology will save lives by making the livers we use function better and by making more organs available for transplantation," said Dr. Markmann.
The OCS™ Liver PROTECT Trial is the first multi-center, randomized clinical trial in the United States for warm liver perfusion for transplantation. It is designed to assess the impact of warm oxygenated perfusion of standard and expanded-criteria donor livers on post-transplant clinical outcomes as compared to cold storage. The trial will be conducted at a network of up to 20 major liver transplant centers in the U.S.
"This is a significant milestone for TransMedics, as it represents the introduction of our third product platform (in addition to our OCS™ Lung and OCS™ Heart platforms), and significantly expands our overall addressable market potential. It solidifies our market leadership position given that OCS is the only multi-organ platform in the market world-wide," said Dr. Waleed Hassanein, President and CEO of TransMedics. "We are committed to continuing to drive medical innovation to make organ transplantation more successful and available for end-stage organ failure patients globally," said Dr. Hassanein.
About TransMedics, Inc.
TransMedics Inc. is the world's leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation. For more information, please visit: www.TransMedics.com.
SOURCE TransMedics, Inc.